+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Biologics Market by Product Type (Cancer Vaccines, Cell Therapy, Gene Therapy), Cancer Type (Breast Cancer, Colorectal Cancer, Hematological Malignancies), End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Cancer Biologics Market by Product Type (Cancer Vaccines, Cell Therapy, Gene Therapy), Cancer Type (Breast Cancer, Colorectal Cancer, Hematological Malignancies), End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Cancer Biologics Market by Product Type (Cancer Vaccines, Cell Therapy, Gene Therapy), Cancer Type (Breast Cancer, Colorectal Cancer, Hematological Malignancies), End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011651
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer biologics market is evolving rapidly, transforming oncology landscapes with precision therapies and strategic collaborations. Senior leaders navigating this arena require insights that clarify growth opportunities, critical challenges, and shifting global supply considerations.

Market Snapshot: Cancer Biologics Market Size and Growth

The cancer biologics market grew from USD 102.05 billion in 2024 to USD 108.88 billion in 2025. It is expected to continue growing at a CAGR of 6.44%, reaching USD 148.45 billion by 2030. This robust pace reflects the rising demand for advanced therapies, driven by innovations in genetic engineering, targeted immune modulation, and improved patient outcomes.

Cancer Biologics Market: Scope & Segmentation

This report delivers a comprehensive breakdown of the cancer biologics landscape, outlining key development segments, delivery frameworks, and target end users. Strategies are examined across global regions, addressing both leading innovation hubs and emerging growth sectors.

  • Product Types: Immunotherapies such as cancer vaccines, cell therapy innovations, gene therapy constructs, monoclonal antibodies (including anti-CD20, anti-HER2, anti-PD-1/PD-L1, and anti-VEGF modalities), and recombinant proteins.
  • Cancer Types: Indications spanning breast cancer, colorectal cancer, hematological malignancies, lung cancer, melanoma, and prostate cancer.
  • End Users: Care providers including ambulatory surgery centers, homecare settings, hospitals and clinics, and specialized oncology centers.
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies, and specialty distributors managing complex fulfillment requirements.
  • Regional Coverage: Markets segmented into the Americas (including the United States, Canada, and Latin America), Europe, Middle East & Africa (with specific highlights such as the United Kingdom, Germany, France, and more), and Asia-Pacific (covering regional powerhouses from China and India to Australia and Southeast Asia).
  • Leading Companies: Competitive profiling includes F. Hoffmann-La Roche Ltd, AbbVie Inc, Bristol-Myers Squibb Company, Merck & Co., Inc., Johnson & Johnson, Amgen Inc, Pfizer Inc, AstraZeneca PLC, Novartis AG, and Gilead Sciences, Inc.

Key Takeaways for Decision-Makers

  • Biologic therapies are now central to oncology practice, shifting standards from traditional regimens toward targeted modalities that prioritize patient safety and efficacy.
  • Major technological advances—including next-generation antibody design and integration of digital diagnostics—are accelerating clinical development and precise patient stratification.
  • Intensified collaboration among pharmaceutical companies, biotechs, academia, and payers is reshaping product pipelines and commercialization strategies.
  • Regional growth strategies are being recalibrated to balance cost-effective production, regulatory compliance, and expansion in both mature and emerging markets.
  • Adaptive regulatory frameworks and real-time data sharing are facilitating earlier market access and supporting ongoing safety evaluations in diverse patient populations.

Tariff Impact on Cancer Biologics Market

Recent tariff policy adjustments are altering supply chain fundamentals for cancer biologics. Manufacturers are adopting flexible sourcing models to address import duties on essential components and raw materials. Strategic moves include supplier diversification and regional manufacturing, aiming to maintain inventory resilience and manage logistic complexity. These factors are prompting firms to reinforce relationships with distributors, engage in transparent pricing negotiations, and explore risk-sharing models to sustain patient access in a fluctuating policy environment.

Primary Keyword Spotlight: Cancer Biologics Market

The cancer biologics market continues to be shaped by converging trends in product innovation, regional expansion, and regulatory adaptation. Integration of artificial intelligence and precision genomics is enhancing the alignment of therapies with patient needs, while ongoing pipeline development forms the basis for long-term portfolio differentiation.

Methodology & Data Sources

This research integrates qualitative interviews with stakeholders, systematic analysis of published literature and public databases, and validation by expert review panels. Primary data from clinical, regulatory, and commercial leaders underpins the insights, supported by triangulation and statistical review processes to ensure accuracy and actionable direction.

Why This Report Matters

  • Enables evidence-based strategic planning for investment, partnership, and expansion in the dynamic cancer biologics sector.
  • Equips decision-makers with segmentation intelligence and regional insights to prioritize R&D and market entry strategies.
  • Supports collaborative alignment among payers, providers, and innovators for improved patient access and competitive results.

Conclusion

This report provides senior leaders with the context and clarity to navigate cancer biologics market trends, optimize growth strategies, and anticipate emerging opportunities. Stakeholders can leverage these insights to strengthen collaboration and advance patient-focused therapeutic innovation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid expansion of CAR-T cell therapies targeting solid tumor antigens resistant to conventional biologics
5.2. Emergence of bispecific antibody constructs bridging T cells with tumor antigens for enhanced cytotoxicity
5.3. Integration of next-generation sequencing data to drive personalized cancer vaccine biologic development
5.4. Growing adoption of antibody-drug conjugates with novel cytotoxic payloads for precision oncology treatment
5.5. Surge in regulatory approvals and fast track designations accelerating checkpoint inhibitor biologics approval
5.6. Advancements in Fc engineering improving half-life and effector functions of therapeutic antibodies
5.7. Increased penetration of biosimilar monoclonal antibodies reshaping cost dynamics in cancer treatment
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Biologics Market, by Product Type
8.1. Introduction
8.2. Cancer Vaccines
8.3. Cell Therapy
8.4. Gene Therapy
8.5. Monoclonal Antibodies
8.5.1. Anti-CD20
8.5.1.1. Obinutuzumab
8.5.1.2. Rituximab
8.5.2. Anti-HER2
8.5.2.1. Pertuzumab
8.5.2.2. Trastuzumab
8.5.3. Anti-PD-1/PD-L1
8.5.3.1. Atezolizumab
8.5.3.2. Nivolumab
8.5.3.3. Pembrolizumab
8.5.4. Anti-VEGF
8.5.4.1. Bevacizumab
8.6. Recombinant Proteins
9. Cancer Biologics Market, by Cancer Type
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Hematological Malignancies
9.5. Lung Cancer
9.6. Melanoma
9.7. Prostate Cancer
10. Cancer Biologics Market, by End User
10.1. Introduction
10.2. Ambulatory Surgery Centers
10.3. Homecare Settings
10.4. Hospitals & Clinics
10.5. Oncology Centers
11. Cancer Biologics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
11.5. Specialty Distributors
12. Americas Cancer Biologics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Cancer Biologics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Cancer Biologics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. F. Hoffmann-La Roche Ltd
15.3.2. AbbVie Inc
15.3.3. Bristol-Myers Squibb Company
15.3.4. Merck & Co., Inc.
15.3.5. Johnson & Johnson
15.3.6. Amgen Inc
15.3.7. Pfizer Inc
15.3.8. AstraZeneca PLC
15.3.9. Novartis AG
15.3.10. Gilead Sciences, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CANCER BIOLOGICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. CANCER BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. CANCER BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. CANCER BIOLOGICS MARKET: RESEARCHAI
FIGURE 24. CANCER BIOLOGICS MARKET: RESEARCHSTATISTICS
FIGURE 25. CANCER BIOLOGICS MARKET: RESEARCHCONTACTS
FIGURE 26. CANCER BIOLOGICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CANCER BIOLOGICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY SPECIALTY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY SPECIALTY DISTRIBUTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 129. CANADA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. CANADA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. CANADA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 132. CANADA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 133. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 134. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 135. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 136. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 137. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 138. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 139. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 140. CANADA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 141. CANADA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 142. CANADA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 143. CANADA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. CANADA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. CANADA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. CANADA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. MEXICO CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 148. MEXICO CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 149. MEXICO CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 150. MEXICO CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 151. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 152. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 153. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 154. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 155. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 156. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 157. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 158. MEXICO CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 159. MEXICO CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 160. MEXICO CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 161. MEXICO CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. MEXICO CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. MEXICO CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. MEXICO CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. GERMANY CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 240. GERMANY CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 241. GERMANY CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 242. GERMANY CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 243. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 244. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 245. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 246. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 247. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 248. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 249. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 250. GERMANY CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 251. GERMANY CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 252. GERMANY CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 253. GERMANY CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. GERMANY CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. GERMANY CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. GERMANY CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. FRANCE CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 258. FRANCE CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 259. FRANCE CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 260. FRANCE CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 261. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 262. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 263. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 264. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 265. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 266. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 267. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 268. FRANCE CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 269. FRANCE CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 270. FRANCE CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 271. FRANCE CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. FRANCE CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. FRANCE CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. FRANCE CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. ITALY CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 294. ITALY CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 295. ITALY CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 296. ITALY CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 297. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 298. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 299. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 300. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 301. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 302. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 303. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 304. ITALY CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 305. ITALY CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 306. ITALY CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 307. ITALY CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. ITALY CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. ITALY CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. ITALY CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. SPAIN CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 312. SPAIN CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 313. SPAIN CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 314. SPAIN CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 315. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 316. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 317. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 318. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 319. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 320. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 321. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 322. SPAIN CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 323. SPAIN CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 324. SPAIN CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 325. SPAIN CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. SPAIN CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. SPAIN CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 328. SPAIN CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 332. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2024 (USD MILLION)
TABLE 334. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2025-2030 (USD MILLION)
TABLE 335. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2024 (USD MILLION)
TABLE 336. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2025-2030 (USD MILLION)
TABLE 337. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2024 (USD MILLION)
TABLE 338. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2025-2030 (USD MILLION)
TABLE 339. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 340. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 341. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 342. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 343. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 344. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 345. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 346. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 347. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 348. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY PRODU

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Cancer Biologics market report include:
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Amgen Inc
  • Pfizer Inc
  • AstraZeneca PLC
  • Novartis AG
  • Gilead Sciences, Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 108.88 Billion
Forecasted Market Value ( USD ) by 2030 $ 148.45 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA - Product Image

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

  • Report
  • 84 Pages
  • Global
From
Cancer Monoclonal Antibodies Market by Mechanism Of Action, Target Antigen, Antibody Type, Therapeutic Indication, Route Of Administration, End User, Formulation - Global Forecast 2025-2030 - Product Image

Cancer Monoclonal Antibodies Market by Mechanism Of Action, Target Antigen, Antibody Type, Therapeutic Indication, Route Of Administration, End User, Formulation - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market by Molecule Class (Anti Cd20, Anti Her2, Anti Vascular Endothelial Growth Factor), Indication (Inflammatory Bowel Disease, Neutropenia, Oncology), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Molecule Class (Anti Cd20, Anti Her2, Anti Vascular Endothelial Growth Factor), Indication (Inflammatory Bowel Disease, Neutropenia, Oncology), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Antibody Discovery - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Antibody Discovery - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From

About the Cancer Biologics Market

The Cancer Biologics market is a subset of the larger Biotechnology industry. It focuses on the development and commercialization of biologic drugs for the treatment of cancer. These drugs are typically derived from living organisms, such as proteins, antibodies, and other molecules, and are used to target and treat cancer cells. They are often used in combination with other treatments, such as chemotherapy and radiation therapy, to improve outcomes. Cancer biologics are typically developed through a combination of laboratory research, clinical trials, and regulatory approval. Companies in this market are typically involved in the research, development, manufacturing, and marketing of these drugs. Notable companies in the Cancer Biologics market include Amgen, Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.